Drug and disease signature integration identifies synergistic combinations in glioblastoma

Vasileios Stathias
Vasileios Stathias
Anna M Jermakowicz
Anna M Jermakowicz
Robert K Suter
Robert K Suter
Nicholas J Lyons
Nicholas J Lyons

Nature communications, Volume 9, Issue 1, 2018, Pages 5315

被引用2|引用|浏览6|来源
WOS

摘要

Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed SynergySeq to identify drug combinations ...更多

代码

数据

您的评分 :
0

 

标签
评论